Page 103 of 440: studies 1,021 to 1,030 of 4,392, newest first. Back to the psilocybin overview
Journal of Psychedelic Studies February 29, 2024 Nicholas Spiers, Beatriz Caiuby Labate, Anna O. Ermakova et al. correction
and has been studying rock art
Psychedelic Medicine February 28, 2024 Joshua Woolley, Amanda E. Downey, Ellen Bradley et al. 2 citations
Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.
Psychedelic Medicine February 28, 2024 Dana D. DiRenzo, Jamie Perin, Erika Darrah et al. 4 citations
This preliminary study suggests that a transient increase in cytokine production ≤1-week postpsilocybin may be found, although not consistently across patient populations. More broadly, peripheral cytokine production is possibly altered by psilocybin administration. ClinicalTrials.gov Identifier: NCT01988311.
Journal of Affective Disorders February 27, 2024 Debora Copa, David Erritzøe, Bruna Giribaldi et al. 31 citations
BackgroundPsilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. Heterogeneous treatment responses raise interest in predicting the outcome from baseline data.MethodsA machine learning pipeline was implemented to investigate baseline resting-state functional connectivity measured with functional magnetic resonance...
International Immunopharmacology February 23, 2024 Salma Laabi, Claire LeMmon, Callie Vogel et al. 16 citations
A decade of clinical research has indicated psilocybin's effectiveness in treating various neuropsychiatric disorders, such as depression and substance abuse. The correlation between increased pro-inflammatory cytokines and the severity of neuropsychiatric symptoms, along with the known anti-inflammatory potential of some psychedelics, suggests an immunomodulatory role for psilocybin. This...
npj Mental Health Research February 20, 2024 Kush V. Bhatt, Cory R. Weissman 29 citations
Psilocybin is a serotonergic psychedelic shown to have enduring antidepressant effects. Currently, the mechanism for its enduring effects is not well understood. Empathy and prosocial behavior may be important for understanding the therapeutic benefit of psilocybin. In this article we review the effect of psilocybin on empathy and prosocial behavior. Moreover, we propose that psilocybin may...
Journal of Psychedelic Studies February 19, 2024 Nicholas Spiers, Beatriz Caiuby Labate, Anna O. Ermakova et al. 27 citations
Abstract This annotated bibliography comprises 49 texts concerning psilocybin mushroom practices developed by Indigenous peoples. The books and articles have been selected for their academic rigor, relevance, and historical significance, and to foreground overlooked research and subject matter. This includes research on a plurality of contemporary practices and evidence of historical uses, from...
Alcoholism & Drug Abuse Weekly February 16, 2024 Alison Knopf
A National Institute on Drug Abuse (NIDA)‐funded study published in the journal Drug and Alcohol Dependence titled “National and Regional Trends in Seizures of Shrooms (Psilocybin) in the United States, 2017‐2022” reported a significant increase in law enforcement seizures of psilocybin mushrooms, also known as “magic mushrooms” or “shrooms,” in the United States from January 2017 to December...
Neuroscience February 16, 2024 Douglas Funk, Joseph Araujo, Malik Slassi et al. 11 citations
Psilocybin has received attention as a treatment for depression, stress disorders and drug and alcohol addiction. To help determine the mechanisms underlying its therapeutic effects, here we examined acute effects of a range of behaviourally relevant psilocybin doses (0.1-3 mg/kg SC) on regional expression of Fos, the protein product of the immediate early gene, c-fos in brain areas involved in...
Frontiers in Psychiatry February 16, 2024 Terence H. W. Ching, Lucia Amoroso, Calvin Bohner et al. correction
[This corrects the article DOI: 10.3389/fpsyt.2023.1278823.].